News
-
-
-
COMMUNIQUÉ DE PRESSE
ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease
ActiTrexx GmbH treats first patient with novel regulatory T cell therapy for Graft-versus-Host Disease. Phase Ib/II study evaluates safety and feasibility of Actileucel treatment